ERIC 2018 | Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells
Kanti Rai
• 25 Oct 2018
Kanti Rai, MD, of the Feinstein Institute of Medical Research, Manhasset, NY, gives us a perceptive insight into advancements in the treatment of chronic lymphocytic leukemia (CLL) over recent years. Prof. Rai highlights BTK inhibitors such as ibrutinib, the BCL-2 inhibitor venetoclax, and anti-CD20 antibodies like rituximab and obinutuzumab, before giving his perspective on the potential of CAR T-cells in this space. This interview recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
